NGL Fine-Chem Limited (NGLFINE.BO)

INR 1116.95

(3.42%)

Total Liabilities Summary of NGL Fine-Chem Limited

NGL Fine-Chem Limited's latest annual total liabilities in 2023 was 929.03 Million INR , up 43.97% from previous year.
NGL Fine-Chem Limited's latest quarterly total liabilities in 2023 FY was 929.03 Million INR , up 43.97% from previous quarter.
NGL Fine-Chem Limited reported annual total liabilities of 645.29 Million INR in 2022, down -12.45% from previous year.
NGL Fine-Chem Limited reported annual total liabilities of 737.09 Million INR in 2021, up 39.26% from previous year.
NGL Fine-Chem Limited reported quarterly total liabilities of 929.03 Million INR for 2023 FY, up 43.97% from previous quarter.
NGL Fine-Chem Limited reported quarterly total liabilities of 812.63 Million INR for 2023 Q2, down 0.0% from previous quarter.

Annual Total Liabilities Chart of NGL Fine-Chem Limited (2023 - 2008)

Historical Annual Total Liabilities of NGL Fine-Chem Limited (2023 - 2008)

Year	Total Liabilities	Total Liabilities Growth
2023	929.03 Million INR	43.97%
2022	645.29 Million INR	-12.45%
2021	737.09 Million INR	39.26%
2020	529.29 Million INR	-3.17%
2019	546.6 Million INR	9.17%
2018	500.67 Million INR	-12.54%
2017	572.49 Million INR	33.92%
2016	427.48 Million INR	29.05%
2015	331.25 Million INR	-1.71%
2014	337 Million INR	7.66%
2013	313.01 Million INR	14.32%
2012	273.8 Million INR	36.33%
2011	200.83 Million INR	28.28%
2010	156.56 Million INR	33.64%
2009	117.15 Million INR	24.34%
2008	94.22 Million INR	0.0%

Year	Total Liabilities	Total Liabilities Growth
2023 Q3	- INR	-100.0%
2023 FY	929.03 Million INR	43.97%
2023 Q2	812.63 Million INR	0.0%
2023 Q1	- INR	-100.0%
2023 Q4	929.03 Million INR	0.0%
2022 FY	645.29 Million INR	-12.45%
2022 Q2	672.27 Million INR	0.0%
2022 Q1	- INR	-100.0%
2022 Q3	- INR	-100.0%
2022 Q4	645.29 Million INR	0.0%
2021 Q2	806.62 Million INR	0.0%
2021 Q3	- INR	-100.0%
2021 Q4	737.09 Million INR	0.0%
2021 FY	737.09 Million INR	39.26%
2021 Q1	- INR	-100.0%
2020 Q2	691.74 Million INR	0.0%
2020 Q4	529.29 Million INR	0.0%
2020 FY	529.29 Million INR	-3.17%
2019 Q4	546.6 Million INR	0.0%
2019 FY	546.6 Million INR	9.17%
2019 Q2	599.48 Million INR	0.0%
2018 FY	500.67 Million INR	-12.54%
2018 Q4	500.67 Million INR	0.0%
2018 Q2	567.82 Million INR	0.0%
2017 Q2	439.8 Million INR	0.0%
2017 Q4	572.49 Million INR	0.0%
2017 FY	572.49 Million INR	33.92%
2016 Q2	307.1 Million INR	0.0%
2016 FY	427.48 Million INR	29.05%
2016 Q4	427.38 Million INR	0.0%
2015 Q2	330.29 Million INR	0.0%
2015 Q4	332.91 Million INR	0.0%
2015 FY	331.25 Million INR	-1.71%
2014 FY	337 Million INR	7.66%
2014 Q4	337 Million INR	0.0%
2014 Q2	355.83 Million INR	0.0%
2013 Q4	313.01 Million INR	0.0%
2013 FY	313.01 Million INR	14.32%
2013 Q2	306.43 Million INR	0.0%
2012 Q4	273.8 Million INR	0.0%
2012 FY	273.8 Million INR	36.33%
2011 Q4	200.83 Million INR	0.0%
2011 FY	200.83 Million INR	28.28%
2010 FY	156.56 Million INR	33.64%
2009 FY	117.15 Million INR	24.34%
2008 FY	94.22 Million INR	0.0%
2008 Q4	94.22 Million INR	0.0%

Peer Total Liabilities Comparison of NGL Fine-Chem Limited

Name	Total Liabilities	Total Liabilities Difference
Abbott India Limited	14.94 Billion INR	93.784%
Cipla Limited	59.15 Billion INR	98.429%
Gland Pharma Limited	19.37 Billion INR	95.205%
GlaxoSmithKline Pharmaceuticals Limited	17.96 Billion INR	94.828%
Kopran Limited	2.52 Billion INR	63.134%
Marksans Pharma Limited	5.95 Billion INR	84.387%
Pfizer Limited	6.33 Billion INR	85.329%
Sanofi India Limited	6.99 Billion INR	86.72%
SMS Pharmaceuticals Limited	4.97 Billion INR	81.336%